Diagnosis and management of systemic light chain AL amyloidosis

被引:5
|
作者
Bhutani, Divaya [1 ]
Lentzsch, Suzanne [1 ]
机构
[1] Columbia Univ, Dept Internal Med, Div Hematol Oncol, Med Ctr, New York, NY 10032 USA
关键词
AL amyloidosis; Diagnosis; Staging; Management; HIGH-DOSE MELPHALAN; CELL TRANSPLANTATION; NATRIURETIC PEPTIDE; LONGITUDINAL STRAIN; PLUS DEXAMETHASONE; IMPROVED OUTCOMES; STAGING SYSTEM; GERMLINE GENE; PHASE; 1/2; BORTEZOMIB;
D O I
10.1016/j.pharmthera.2020.107612
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AL amyloidosis is a plasma cell disorder leading to the production and extracellular deposition of abnormal immunoglobulin light chains called amyloid. The pathogenesis of the disorder is driven by an abnormal plasma cell clone producing excessive monoclonal immunoglobulin light chains that undergo deposition in various organs of the body such as the heart, kidney, and gastrointestinal tract. The outcome of the disease remains poor with significant morbidity and mortality associated with organ dysfunction. In this review, we describe the current standard diagnostic features, prognosis, and current treatment paradigm of the disease. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Light chain (AL) amyloidosis: update on diagnosis and management
    Michael Rosenzweig
    Heather Landau
    [J]. Journal of Hematology & Oncology, 4
  • [2] Light chain (AL) amyloidosis: update on diagnosis and management
    Rosenzweig, Michael
    Landau, Heather
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [3] Light Chain (AL) Amyloidosis: The Journey to Diagnosis
    McCausland, Kristen L.
    White, Michelle K.
    Guthrie, Spencer D.
    Quock, Tiffany
    Finkel, Muriel
    Lousada, Isabelle
    Bayliss, Martha S.
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 11 (02): : 207 - 216
  • [4] Light Chain (AL) Amyloidosis: The Journey to Diagnosis
    Kristen L. McCausland
    Michelle K. White
    Spencer D. Guthrie
    Tiffany Quock
    Muriel Finkel
    Isabelle Lousada
    Martha S. Bayliss
    [J]. The Patient - Patient-Centered Outcomes Research, 2018, 11 : 207 - 216
  • [5] Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis
    Vaxman, Iuliana
    Gertz, Morie
    [J]. ACTA HAEMATOLOGICA, 2019, 141 (02) : 93 - 106
  • [6] Light-chain (AL) amyloidosis: Diagnosis and treatment
    Sanchorawala, Vaishali
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06): : 1331 - 1341
  • [7] Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Kastritis, Efstathios
    [J]. HEMASPHERE, 2020, 4 (04):
  • [8] Systemic AL (light-chain) amyloidosis and the gastrointestinal tract
    Sattianayagam, Prayman
    Gibbs, Simon
    Hawkins, Philip
    Gillmore, Julian
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (11) : 1384 - 1385
  • [9] Systemic Light Chain Amyloidosis
    Sanchorawala, Vaishali
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (24): : 2295 - 2307
  • [10] What is new in diagnosis and management of light chain amyloidosis?
    Palladini, Giovanni
    Merlini, Giampaolo
    [J]. BLOOD, 2016, 128 (02) : 159 - 168